Since the first patient in January 2021, the EAP program has provided belvarafenib for 16 melanoma patients harboring various RAS and RAF mutations as shown in Table 2, including 11 patients with NRAS missense mutations, 2 patients harboring BRAF missense mutations, and 3 patients with RAF fusions (LMBR1–BRAF, AGK–BRAF, MIPOL–RAF1). Here, BRAF is linked to melanoma.